News | January 20, 2022
Natco Pharma signs agreement with Medicines Patent Pool
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
They will commercialize molnupiravir in the international markets
It is the first monoclonal antibody drug for use in any animal species
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
This surpasses the number of approvals supported in 2020
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Subscribe To Our Newsletter & Stay Updated
